Hsa-miR-105-1 Regulates Cisplatin-Resistance in Ovarian Carcinoma Cells by Targeting ANXA9

PURPOSE: Cisplatin is one of the most effective drugs for treating ovarian carcinoma (OC), which is among the most lethal types of carcinoma. However, the chemoresistance to cisplatin that develops over time leads to a poor clinical outcome for many OC patients. Therefore, it is necessary to clearly...

Descripción completa

Detalles Bibliográficos
Autores principales: Kou, Xinxin, Ding, Hui, Li, Lei, Chao, Hongtu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929659/
https://www.ncbi.nlm.nih.gov/pubmed/33680718
http://dx.doi.org/10.1155/2021/6662486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929659/
https://www.ncbi.nlm.nih.gov/pubmed/33680718
http://dx.doi.org/10.1155/2021/6662486

Ejemplares similares